Pre-made Axatilimab biosimilar ( Whole mAb, anti-CSF1R therapeutic antibody, Anti-FMS/CSFR/FIM2/HDLS/C-FMS/CD115/HDLS1/CSF-1R/BANDDOS/M-CSF-R Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Axatilimab biosimilar, Whole mAb, Anti-CSF1R Antibody: Anti-FMS/CSFR/FIM2/HDLS/C-FMS/CD115/HDLS1/CSF-1R/BANDDOS/M-CSF-R therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Axatilimab (SNDX-6352) is a high-affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). … Axatilimab (SNDX-6352) is a high-affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R).
| Products Name (INN Index) | Pre-Made Axatilimab biosimilar, Whole mAb, Anti-CSF1R Antibody: Anti-FMS/CSFR/FIM2/HDLS/C-FMS/CD115/HDLS1/CSF-1R/BANDDOS/M-CSF-R therapeutic antibody |
|---|---|
| INN Name | Axatilimab |
| Target | CSF1R |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Syndax Pharmaceuticals,AstraZeneca,UCB |
| Conditions Approved | NA |
| Conditions Active | Cholangiocarcinoma,Graft-versus-host disease,COVID-19 |
| Conditions Discontinued | Solid tumours |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CSF1R |
| Package |
